- Acorda Therapeutics
- according to Bloomberg's Natasha Rausch.
- Read Bloomberg's full story here.
ADVERTISEMENT
Acorda Therapeutics crashes 40% after patients die in drug trial (ACOR)
The drug company was in the final stages of a drug trial when several people in the trial died.
ADVERTISEMENT
FOLLOW BUSINESS INSIDER AFRICA
ADVERTISEMENT